Amgen (AMGN) And Kyowa Kirin Reveal Initial Results From Rocatinlimab ASCEND Study

Amgen (AMGN) and Kyowa Kirin Co., Ltd. announced promising preliminary results from their ASCEND study, focusing on a new therapy for atopic dermatitis, which could potentially pique investor interest. Despite this development, Amgen's stock saw a 2.42% decline last week, subtly countering the broader market movements where indices like the S&P 500 and Nasdaq reached all-time highs. The company's recent collaborations and forward-looking statements provide a context of optimism and opportunity, yet the broader market’s positive momentum amid lower PPI data and strong performance in tech shares might have overshadowed these developments.

Amgen has 2 weaknesses we think you should know about.

We've found 18 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

The promising preliminary results from Amgen's ASCEND study with Kyowa Kirin could influence the company's narrative by potentially mitigating some concerns about revenue and margin erosion due to aging therapies and patent expirations. Successful new therapies may enhance Amgen’s revenue growth and earnings resilience amidst pricing and regulatory pressures. Over a longer three-year period, Amgen's total shareholder returns were 35.79%, providing a broader context of appreciation despite recent week declines. This performance contrasts to a more challenging past year where Amgen underperformed the US market's 20% return and lagged the Biotechs industry’s negative 5.8% return.

The impact of the ASCEND study results might play an integral role in shaping future revenue and earnings forecasts, offering a catalyst that could potentially offset current margin compressions and enhance shareholder returns. Amgen's current share price of $279.97 reflects a discount of about 11.4% compared to the consensus analyst price target of $311.88, potentially signaling underappreciated risks or future growth prospects under current market conditions. Should the ASCEND study outcomes positively influence future earnings and revenue, the analysts' estimates and, by extension, the price target may be re-evaluated over time.

Dive into the specifics of Amgen here with our thorough balance sheet health report.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com